Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Clinical resistance to the second-generation antiandrogen enzalutamide in castration resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights the unmet medical need for next generation antagonists. We have identified and characterized tetra-aryl cycl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, Julie A., Wardell, Suzanne E., Parent, Alexander A., Stagg, David B., Ellison, Stephanie J., Alley, Holly M., Chao, Christina A., Lawrence, Scott A., Stice, James P., Spasojevic, Ivan, Baker, Jennifer G., Kim, Sung Hoon, McDonnell, Donald P., Katzenellenbogen, John A., Norris, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030124/
https://www.ncbi.nlm.nih.gov/pubmed/27501397
http://dx.doi.org/10.1038/nchembio.2131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030124/
https://www.ncbi.nlm.nih.gov/pubmed/27501397
http://dx.doi.org/10.1038/nchembio.2131

Ejemplares similares